Prof. Mathias Uhlén has invested in Capitainer AB, and joined the company’s advisory board, the Swedish medtech company announced today. Mathias Uhlén is a world-leading scientist in biotechnology and proteomics, as well as a successful serial entrepreneur.
Mathias Uhlén, biotechnologist, entrepreneur, and Professor of Microbiology at the Royal Institute of Technology (KTH), Stockholm, is investing in the Swedish medtech company Capitainer and joining the advisory board.
Professor Uhlén is widely known for his work in large-scale quantitative analysis of proteins and leadership of the Human Protein Atlas project. He was also the Founding Director of the Science for Life Laboratory, SciLifeLab, 2010–2015. Mathias Uhlén’s research interests cover antibody engineering, proteomics, and precision medicine.
“We are more than delighted to have Mathias Uhlén on board. His grit, knowledge, and experience of breaking new ground is an invaluable asset for Capitainer as we are taking a leap into the world of proteomics assays,” says Christopher Aulin, CEO of Capitainer.
Mathias Uhlén’s research has led to over 750 publications in scientific journals. His work has been translated by several companies ranging from early start-ups to large international companies, developing industrial applications of his research. He has founded 20 companies and has more than 70 international patent applications.
“I am thrilled to be part of the Capitainer advisory board, and I see great potential in the technologies Capitainer provides. Capitainer’s products, delivering high precision accuracy blood and plasma sampling, are the missing link to enable a broader implementation of personalised medicine, proteomics, and clinical monitoring in today’s healthcare, says Mathias Uhlén.
Already in collaboration with Mathias Uhlén and researchers at SciLifeLab, Capitainer is developing new specialised solutions for personalised medicine. The work is based on Capitainer’s products and analysis using proteomics assays developed by research and infrastructure groups at the Department of Protein Science, KTH.
“Through these joint efforts using our technologies, we have a unique possibility to play a crucial role in the commercialisation of large-scale screenings and personalised medicine diagnostics,” says Christopher Aulin.
Professor Mathias Uhlén is a member of the Royal Swedish Academy of Engineering Science, IVA, the Royal Swedish Academy of Science, KVA, the European Molecular Biology Organization, EMBO, and a member of the National Academy of Engineering (USA). He was the President of the European Federation of Biotechnology between 2015 and 2020.
He is also a former member of the board of directors of listed companies, including Prevas, Skanditek, Alligator Bioscience, Amersham, Novozymes, Bure and Biotage.
